Psychedelics field looks ahead after FDA advisers' rejection.
Science (New York, N.Y.) June 14, 2024 DOI: 10.1126/science.adr0286 via PubMed
Summary
AI-generated from the abstractAfter the FDA rejected MDMA-assisted therapy for PTSD, researchers are analyzing what went wrong and how to improve future clinical trials. The negative vote highlights concerns about study design, potential bias, and the need for more rigorous methodologies in psychedelic research. Lessons include the importance of adequate blinding, managing expectancy effects, and ensuring data integrity. The field must address these challenges to advance regulatory approval for psychedelic treatments.
Study at a glance
| Characteristics | Commentary or analysis Peer reviewed |
|---|---|
| Keywords | Psychedelic-medicine MDMA-Therapy Clinical-trials Drug-regulation Mental-health-treatment |
| Citations | 3 |
| Key finding | The FDA's rejection of MDMA-assisted PTSD therapy underscores the need for improved trial designs to address bias and methodological flaws in psychedelic research. |
Abstract
Reeling from negative vote on MDMA-assisted PTSD therapy, researchers seek lessons for future studies.